Pfizer Property Plant And Equipment Gross vs Non Current Liabilities Total Analysis
PFE Stock | USD 25.40 0.14 0.55% |
Pfizer financial indicator trend analysis is much more than just breaking down Pfizer Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pfizer Inc is a good investment. Please check the relationship between Pfizer Property Plant And Equipment Gross and its Non Current Liabilities Total accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
Property Plant And Equipment Gross vs Non Current Liabilities Total
Property Plant And Equipment Gross vs Non Current Liabilities Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pfizer Inc Property Plant And Equipment Gross account and Non Current Liabilities Total. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Pfizer's Property Plant And Equipment Gross and Non Current Liabilities Total is 0.51. Overlapping area represents the amount of variation of Property Plant And Equipment Gross that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Pfizer Inc, assuming nothing else is changed. The correlation between historical values of Pfizer's Property Plant And Equipment Gross and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant And Equipment Gross of Pfizer Inc are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Property Plant And Equipment Gross i.e., Pfizer's Property Plant And Equipment Gross and Non Current Liabilities Total go up and down completely randomly.
Correlation Coefficient | 0.51 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Property Plant And Equipment Gross
Non Current Liabilities Total
Most indicators from Pfizer's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. At present, Pfizer's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 240.8 B, whereas Tax Provision is projected to grow to (1.1 B).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 50.5B | 66.0B | 29.3B | 30.4B | Total Revenue | 81.3B | 100.3B | 58.5B | 39.5B |
Pfizer fundamental ratios Correlations
Click cells to compare fundamentals
Pfizer Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pfizer fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 167.5B | 154.2B | 181.5B | 197.2B | 226.5B | 237.8B | |
Short Long Term Debt Total | 52.1B | 38.3B | 37.0B | 34.9B | 75.0B | 78.8B | |
Total Current Liabilities | 37.3B | 25.9B | 42.7B | 42.1B | 47.8B | 50.2B | |
Total Stockholder Equity | 63.1B | 63.2B | 77.2B | 95.7B | 89.0B | 46.9B | |
Property Plant And Equipment Net | 14.0B | 13.9B | 14.9B | 16.3B | 18.9B | 11.3B | |
Net Debt | 50.8B | 36.5B | 35.1B | 34.5B | 72.2B | 75.8B | |
Retained Earnings | 97.7B | 96.8B | 103.4B | 125.7B | 118.4B | 124.3B | |
Cash | 1.3B | 1.8B | 1.9B | 416M | 2.9B | 2.0B | |
Non Current Assets Total | 134.7B | 119.2B | 121.8B | 145.9B | 183.2B | 192.3B | |
Non Currrent Assets Other | 4.5B | 4.6B | 7.7B | 13.2B | 9.1B | 5.3B | |
Cash And Short Term Investments | 9.8B | 12.2B | 31.1B | 22.7B | 12.7B | 14.9B | |
Net Receivables | 12.1B | 11.2B | 15.7B | 14.5B | 11.2B | 8.7B | |
Common Stock Shares Outstanding | 5.7B | 5.6B | 5.7B | 5.7B | 5.7B | 5.7B | |
Liabilities And Stockholders Equity | 167.5B | 154.2B | 181.5B | 197.2B | 226.5B | 237.8B | |
Non Current Liabilities Total | 66.7B | 64.8B | 61.3B | 59.2B | 89.4B | 93.9B | |
Inventory | 8.3B | 8.0B | 9.1B | 9.0B | 10.2B | 5.2B | |
Other Current Assets | 2.6B | 3.4B | 3.8B | 5.0B | 9.3B | 9.7B | |
Other Stockholder Equity | (23.4B) | (22.3B) | (20.8B) | (22.2B) | (21.9B) | (20.8B) | |
Total Liab | 104.0B | 90.8B | 104.0B | 101.3B | 137.2B | 144.1B | |
Property Plant And Equipment Gross | 14.0B | 28.4B | 30.0B | 31.4B | 35.0B | 36.7B | |
Total Current Assets | 32.8B | 35.1B | 59.7B | 51.3B | 43.3B | 32.2B | |
Short Term Debt | 16.2B | 2.7B | 2.2B | 2.9B | 10.9B | 5.7B | |
Intangible Assets | 35.4B | 28.5B | 25.1B | 43.4B | 64.9B | 68.1B | |
Property Plant Equipment | 14.0B | 13.9B | 14.9B | 16.3B | 18.9B | 11.3B | |
Accounts Payable | 4.2B | 4.3B | 5.6B | 6.8B | 6.7B | 7.0B | |
Accumulated Other Comprehensive Income | (11.6B) | (11.7B) | (5.9B) | (8.3B) | (8.0B) | (7.6B) | |
Common Stock Total Equity | 468M | 470M | 473M | 476M | 478M | 474.0M | |
Short Term Investments | 8.5B | 10.4B | 29.1B | 22.3B | 9.8B | 9.3B | |
Capital Stock | 468M | 470M | 473M | 476M | 478M | 474.0M | |
Common Stock | 468M | 470M | 473M | 476M | 478M | 474.0M | |
Other Liab | 29.7B | 26.6B | 22.6B | 23.3B | 26.9B | 22.1B | |
Other Assets | 4.2B | 4.3B | 5.6B | 6.8B | 6.7B | 5.0B | |
Long Term Debt | 36.0B | 37.1B | 36.2B | 32.9B | 60.5B | 63.5B | |
Good Will | 58.7B | 49.6B | 49.2B | 51.4B | 67.8B | 40.7B | |
Treasury Stock | (110.8B) | (111.0B) | (111.4B) | (114.0B) | (114.5B) | (108.8B) | |
Current Deferred Revenue | 5.8B | 6.3B | 3.1B | 2.5B | 2.7B | 3.9B | |
Net Tangible Assets | (30.9B) | 63.2B | 77.2B | 95.7B | 89.0B | 93.5B |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.